{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:26:08Z","timestamp":1757312768262,"version":"3.37.3"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00228-024-03621-9","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T13:02:00Z","timestamp":1705496520000},"page":"481-492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tofacitinib for the treatment of severe rare skin diseases: a narrative review"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1425-0895","authenticated-orcid":false,"given":"Fenglin","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1424-7774","authenticated-orcid":false,"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6206-8073","authenticated-orcid":false,"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"3621_CR1","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","volume":"389","author":"P Joly","year":"2017","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D\u2019Incan M, Bedane C, B\u00e9n\u00e9ton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P, French study group on autoimmune bullous skin diseases, (2017) First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 389:2031\u20132040. https:\/\/doi.org\/10.1016\/S0140-6736(17)30070-3","journal-title":"Lancet"},{"key":"3621_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221\u2013232. https:\/\/doi.org\/10.1056\/NEJMoa0909905","journal-title":"N Engl J Med"},{"key":"3621_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM (2017) JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 77:521\u2013546. https:\/\/doi.org\/10.1007\/s40265-017-0701-9","journal-title":"Drugs"},{"key":"3621_CR4","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","volume":"77","author":"S Dhillon","year":"2017","unstructured":"Dhillon S (2017) Tofacitinib: a review in rheumatoid arthritis. Drugs 77:1987\u20132001. https:\/\/doi.org\/10.1007\/s40265-017-0835-9","journal-title":"Drugs"},{"key":"3621_CR5","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","volume":"398","author":"Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, Vyzhga Y, Marzan K, Grebenkina L, Tirosh I, Imundo L, Jerath R, Kingsbury DJ, Sozeri B, Vora SS, Prahalad S, Zholobova E, Butbul Aviel Y, Chasnyk V, Lerman M, Nanda K, Schmeling H, Tory H, Uziel Y, Viola DO, Posner HB, Kanik KS, Wouters A, Chang C, Zhang R, Lazariciu I, Hsu MA, Suehiro RM, Martini A, Lovell DJ, Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)","year":"2021","unstructured":"Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, Vyzhga Y, Marzan K, Grebenkina L, Tirosh I, Imundo L, Jerath R, Kingsbury DJ, Sozeri B, Vora SS, Prahalad S, Zholobova E, Butbul Aviel Y, Chasnyk V, Lerman M, Nanda K, Schmeling H, Tory H, Uziel Y, Viola DO, Posner HB, Kanik KS, Wouters A, Chang C, Zhang R, Lazariciu I, Hsu MA, Suehiro RM, Martini A, Lovell DJ, Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG) (2021) Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet 398:1984\u20131996. https:\/\/doi.org\/10.1016\/S0140-6736(21)01255-1","journal-title":"Lancet"},{"key":"3621_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","volume":"88","author":"J Zhang","year":"2017","unstructured":"Zhang J, Tsai TF, Lee MG, Zheng M, Wang G, Jin HZ, Gu J, Li R, Liu QZ, Chen J, Tu C, Qi CM, Zhu H, Ports WC, Crook T (2017) The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a Phase 3, randomized, double-blind, placebo-controlled study. J Dermatol Sci 88:36\u201345. https:\/\/doi.org\/10.1016\/j.jdermsci.2017.05.004","journal-title":"J Dermatol Sci"},{"key":"3621_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jdcr.2023.01.020","volume":"33","author":"N Shahriari","year":"2023","unstructured":"Shahriari N, Strober B, Shahriari M (2023) JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: a case series of 6 patients. JAAD Case Rep 33:81\u201383. https:\/\/doi.org\/10.1016\/j.jdcr.2023.01.020","journal-title":"JAAD Case Rep"},{"key":"3621_CR8","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1111\/ijd.16323","volume":"62","author":"DJ Aickara","year":"2023","unstructured":"Aickara DJ, Patel S, Rosen J, Alonso-Llamazares J (2023) Significant improvement of vitiligo with oral tofacitinib treatment. Int J Dermatol 62:e358\u2013e360. https:\/\/doi.org\/10.1111\/ijd.16323","journal-title":"Int J Dermatol"},{"key":"3621_CR9","doi-asserted-by":"publisher","unstructured":"Perche P, Purvis C, Pichardo R (2022) Refractory alopecia areata and vitiligo responding to tofacitinib monotherapy. J Drugs Dermatol 21:1366\u20131368. https:\/\/doi.org\/10.36849\/JDD.6826","DOI":"10.36849\/JDD.6826"},{"key":"3621_CR10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA (2017) JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 76:736\u2013744. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.005","journal-title":"J Am Acad Dermatol"},{"key":"3621_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/bjd\/ljac078","volume":"188","author":"B Fan","year":"2023","unstructured":"Fan B, Wang M (2023) Tofacitinib in recalcitrant bullous pemphigoid: a report of seven cases. Br J Dermatol 188:432\u2013434. https:\/\/doi.org\/10.1093\/bjd\/ljac078","journal-title":"Br J Dermatol"},{"key":"3621_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdcr.2022.10.028","volume":"32","author":"S Youssef","year":"2023","unstructured":"Youssef S, Gallitano S, Bordone LA (2023) Two cases of bullous pemphigoid effectively treated with oral tofacitinib. JAAD Case Rep 32:77\u201380. https:\/\/doi.org\/10.1016\/j.jdcr.2022.10.028","journal-title":"JAAD Case Rep"},{"key":"3621_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1089\/derm.2022.29007.bfa","volume":"34","author":"B Fan","year":"2023","unstructured":"Fan B, Wang M (2023) Tofacitinib, a JAK1\/3 inhibitor as treatment for linear IgA bullous dermatosis: a case report. Dermatitis 34:160\u2013161. https:\/\/doi.org\/10.1089\/derm.2022.29007.bfa","journal-title":"Dermatitis"},{"key":"3621_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/jamadermatol.2022.6250","volume":"159","author":"B Fan","year":"2023","unstructured":"Fan B, Wang M (2023) Treatment of recurrent epidermolysis bullosa acquisita with tofacitinib. JAMA Dermatol 159:342\u2013344. https:\/\/doi.org\/10.1001\/jamadermatol.2022.6250","journal-title":"JAMA Dermatol"},{"key":"3621_CR15","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/ced.14998","volume":"47","author":"KJ Chen","year":"2022","unstructured":"Chen KJ, Fang S, Ye Q, Jia M (2022) Successful use of tofacitinib in epidermolysis bullosa pruriginosa. Clin Exp Dermatol 47:598\u2013600. https:\/\/doi.org\/10.1111\/ced.14998","journal-title":"Clin Exp Dermatol"},{"key":"3621_CR16","doi-asserted-by":"publisher","first-page":"110591","DOI":"10.1016\/j.intimp.2023.110591","volume":"122","author":"H Li","year":"2023","unstructured":"Li H, Wang H, Qiao G, Liu Y, Zhang F, Pan F (2023) Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: a case report and review of the literature. Int Immunopharmacol 122:110591. https:\/\/doi.org\/10.1016\/j.intimp.2023.110591","journal-title":"Int Immunopharmacol"},{"key":"3621_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40001-022-00693-0","volume":"27","author":"M Luo","year":"2022","unstructured":"Luo M, Chen L, He H, He F (2022) Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib. Eur J Med Res 27:68. https:\/\/doi.org\/10.1186\/s40001-022-00693-0","journal-title":"Eur J Med Res"},{"key":"3621_CR18","doi-asserted-by":"publisher","unstructured":"Rathore U, Nigam N, Aggarwal A, Gupta L (2022) Panniculitis as the transformed cutaneous manifestation of refractory dermatomyositis with successful management with tofacitinib. Mediterr J Rheumatol 33:380\u2013382. https:\/\/doi.org\/10.31138\/mjr.33.3.380","DOI":"10.31138\/mjr.33.3.380"},{"key":"3621_CR19","doi-asserted-by":"publisher","first-page":"01","DOI":"10.1136\/rmdopen-2022-002795","volume":"9","author":"T Ida","year":"2023","unstructured":"Ida T, Furuta S, Takayama A, Tamura J, Hayashi Y, Abe K, Kurihara S, Ishikawa J, Iwamoto T, Ikeda K, Suzuki K, Nakajima H (2023) Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD Open 9:01. https:\/\/doi.org\/10.1136\/rmdopen-2022-002795","journal-title":"RMD Open"},{"key":"3621_CR20","doi-asserted-by":"publisher","first-page":"105532","DOI":"10.1016\/j.jbspin.2023.105532","volume":"90","author":"M Robert","year":"2023","unstructured":"Robert M, Gallay L, Garnier L, Pescarmona R, Hot A (2023) Contribution of the interferon score in the management of an anti-NXP2 dermatomyositis patient with calcinosis successfully treated with tofacitinib. Joint Bone Spine 90:105532. https:\/\/doi.org\/10.1016\/j.jbspin.2023.105532","journal-title":"Joint Bone Spine"},{"key":"3621_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/mrcr\/rxac049","volume":"7","author":"S Hama","year":"2023","unstructured":"Hama S, Akiyama M, Higashida-Konishi M, Oshige T, Takei H, Izumi K, Oshima H, Okano Y (2023) Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis. Mod Rheumatol Case Rep 7:92\u201395. https:\/\/doi.org\/10.1093\/mrcr\/rxac049","journal-title":"Mod Rheumatol Case Rep"},{"key":"3621_CR22","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1136\/ard-2023-223919","volume":"82","author":"Y Xue","year":"2023","unstructured":"Xue Y, Zhang J, Deng J, Kuang W, Wang J, Tan X, Li C, Li S, Li C (2023) Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients. Ann Rheum Dis 82:1499\u20131501. https:\/\/doi.org\/10.1136\/ard-2023-223919","journal-title":"Ann Rheum Dis"},{"key":"3621_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/1756-185X.14258","volume":"25","author":"PLP Chan Ng","year":"2022","unstructured":"Chan Ng PLP, Mopur A, Goh DYT, Ramamurthy MB, Lim MTC, Lim LK, Ooi PL, Ang EY (2022) Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease. Int J Rheum Dis 25:228\u2013231. https:\/\/doi.org\/10.1111\/1756-185X.14258","journal-title":"Int J Rheum Dis"},{"key":"3621_CR24","doi-asserted-by":"publisher","unstructured":"Nallapati A, Wigley FM, Paik JJ (2022) Improvement of salt and pepper skin changes in diffuse Scleroderma after treatment with tofacitinib. Clin Exp Rheumatol 40:2008\u20132009. https:\/\/doi.org\/10.55563\/clinexprheumatol\/znqm6v","DOI":"10.55563\/clinexprheumatol\/znqm6v"},{"key":"3621_CR25","doi-asserted-by":"publisher","first-page":"e34125","DOI":"10.7759\/cureus.34125","volume":"15","author":"J \u00c1lvarez Troncoso","year":"2023","unstructured":"\u00c1lvarez Troncoso J, Nu\u00f1o Gonz\u00e1lez A, Mart\u00ednez Robles E, Sorriguieta Torre R, Robles Marhuenda \u00c1 (2023) Tofacitinib is an effective treatment for refractory scleromyositis associated with anti-PM\/Scl. Cureus 15:e34125. https:\/\/doi.org\/10.7759\/cureus.34125","journal-title":"Cureus"},{"key":"3621_CR26","doi-asserted-by":"publisher","unstructured":"Tang JC, Zheng WY, Han GM, Liu SF, Yang B (2023) Successful treatment of paediatric morphea with tofacitinib. Acta Derm Venereol 103:adv4805. https:\/\/doi.org\/10.2340\/actadv.v103.4805","DOI":"10.2340\/actadv.v103.4805"},{"key":"3621_CR27","doi-asserted-by":"publisher","first-page":"e15942","DOI":"10.1111\/dth.15942","volume":"35","author":"L Liu","year":"2022","unstructured":"Liu L, Zhan Y, Shi Y, Zeng Z, Yu J, Zou P, Qiu X, Zhou Y, Zhang G, Ding Y, Xiao R (2022) Bullous lichen sclerosus-generalized morphea overlap syndrome improved by tofacitinib. Dermatol Ther 35:e15942. https:\/\/doi.org\/10.1111\/dth.15942","journal-title":"Dermatol Ther"},{"key":"3621_CR28","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1111\/1756-185X.14693","volume":"26","author":"F Cao","year":"2023","unstructured":"Cao F, Hou X, Kang T, Shi X, Ma W, Zhang Y, Li C (2023) SAPHO syndrome complicated with relapsing polychondritis: a case report. Int J Rheum Dis 26:2060\u20132063. https:\/\/doi.org\/10.1111\/1756-185X.14693","journal-title":"Int J Rheum Dis"},{"key":"3621_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40744-022-00496-z","volume":"10","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Ru J, Zhang J (2023) Sequential tocilizumab and tofacitinib treatment for systemic juvenile idiopathic arthritis: a case report. Rheumatol Ther 10:293\u2013300. https:\/\/doi.org\/10.1007\/s40744-022-00496-z","journal-title":"Rheumatol Ther"},{"key":"3621_CR30","doi-asserted-by":"publisher","first-page":"e15780","DOI":"10.1111\/dth.15780","volume":"35","author":"J Ma","year":"2022","unstructured":"Ma J, Lu W, Yan D, Liu Z, Xue L (2022) Tofacitinib for the treatment of refractory or glucocorticoid-dependent cutaneous leukocytoclastic vasculitis. Dermatol Ther 35:e15780. https:\/\/doi.org\/10.1111\/dth.15780","journal-title":"Dermatol Ther"},{"key":"3621_CR31","doi-asserted-by":"publisher","first-page":"e15932","DOI":"10.1111\/dth.15932","volume":"35","author":"P Mansouri","year":"2022","unstructured":"Mansouri P, Mozafari N, Chalangari R, Martits-Chalangari K (2022) Efficacy of oral tofacitinib in refractory chronic spontaneous urticaria and urticarial vasculitis. Dermatol Ther 35:e15932. https:\/\/doi.org\/10.1111\/dth.15932","journal-title":"Dermatol Ther"},{"key":"3621_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/03009742.2021.1911054","volume":"51","author":"CR Wang","year":"2022","unstructured":"Wang CR, Tsai YS, Liu YW, Li YH (2022) Extended-release tofacitinib improves refractory Takayasu\u2019s arteritis. Scand J Rheumatol 51:72\u201375. https:\/\/doi.org\/10.1080\/03009742.2021.1911054","journal-title":"Scand J Rheumatol"},{"key":"3621_CR33","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/1756-185X.14628","volume":"26","author":"C Ru","year":"2023","unstructured":"Ru C, Qian T, Liu X, Wang C, Li W, Hou X, Li C (2023) SAPHO syndrome with Takayasu arteritis successfully treated with tofacitinib. Int J Rheum Dis 26:1381\u20131383. https:\/\/doi.org\/10.1111\/1756-185X.14628","journal-title":"Int J Rheum Dis"},{"key":"3621_CR34","doi-asserted-by":"publisher","unstructured":"Ino K, Kinoshita N, Arinuma Y, Matsueda Y, Yamaoka K (2022) Improvements in PET\/CT results and serum cytokine profile of HLA-B52-positive patients with Takayasu\u2019s arteritis and ulcerative colitis post-tofacitinib. Clin Exp Rheumatol 40:849\u2013850. https:\/\/doi.org\/10.55563\/clinexprheumatol\/i9chku","DOI":"10.55563\/clinexprheumatol\/i9chku"},{"key":"3621_CR35","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s10067-023-06506-x","volume":"42","author":"K Bhowmick","year":"2023","unstructured":"Bhowmick K, Roongta R, Dey S, Dey S, Mondal S, Sinhamahapatra P, Ghosh P, Ghosh B (2023) Refractory Takayasu arteritis with recurrent pyoderma gangrenosum: a therapeutic challenge with case-based review. Clin Rheumatol 42:1469\u20131477. https:\/\/doi.org\/10.1007\/s10067-023-06506-x","journal-title":"Clin Rheumatol"},{"key":"3621_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12886-023-02966-6","volume":"23","author":"Y Wang","year":"2023","unstructured":"Wang Y, Tang S, Shao C, Liu Y (2023) Cogan\u2019s syndrome is more than just keratitis: a case-based literature review. BMC Ophthalmol 23:212. https:\/\/doi.org\/10.1186\/s12886-023-02966-6","journal-title":"BMC Ophthalmol"},{"key":"3621_CR37","doi-asserted-by":"publisher","first-page":"981502","DOI":"10.3389\/fimmu.2022.981502","volume":"13","author":"N Zhao","year":"2022","unstructured":"Zhao N, Tang Y, Wang S, Cui L, Sun X, Wang Z, Liu Y (2022) Case report: Refractory intestinal Beh\u00e7et\u2019s syndrome successfully treated with tofacitinib: a report of four cases. Front Immunol 13:981502. https:\/\/doi.org\/10.3389\/fimmu.2022.981502","journal-title":"Front Immunol"},{"key":"3621_CR38","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/jgh.15997","volume":"38","author":"M Lin","year":"2023","unstructured":"Lin M, Tang J, Huang Z, Gao X, Chao K (2023) Gastrointestinal: Refractory parastomal ulcers of Behcet\u2019s disease responsive to tofacitinib. J Gastroenterol Hepatol 38:485. https:\/\/doi.org\/10.1111\/jgh.15997","journal-title":"J Gastroenterol Hepatol"},{"key":"3621_CR39","doi-asserted-by":"publisher","first-page":"e29189","DOI":"10.1097\/MD.0000000000029189","volume":"101","author":"CR Wang","year":"2022","unstructured":"Wang CR, Wong TW, Hsu SM (2022) Extended-release tofacitinib for refractory Beh\u00e7et disease: a case report. Medicine 101:e29189. https:\/\/doi.org\/10.1097\/MD.0000000000029189","journal-title":"Medicine"},{"key":"3621_CR40","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/ijd.16676","volume":"62","author":"LGM Castro","year":"2023","unstructured":"Castro LGM (2023) JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum. Int J Dermatol 62:1088\u20131093. https:\/\/doi.org\/10.1111\/ijd.16676","journal-title":"Int J Dermatol"},{"key":"3621_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jdcr.2022.09.030","volume":"30","author":"YF Xu","year":"2022","unstructured":"Xu YF, Li ZQ, Yang WS, Shi XW, Han GM (2022) Successful treatment of refractory IgA vasculitis with tofacitinib. JAAD Case Rep 30:63\u201365. https:\/\/doi.org\/10.1016\/j.jdcr.2022.09.030","journal-title":"JAAD Case Rep"},{"key":"3621_CR42","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2147\/CCID.S392909","volume":"16","author":"R Wang","year":"2023","unstructured":"Wang R, Li Y, Liu Y, Hou X, Li C (2023) Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome with Henoch-Sch\u00f6nlein purpura: a case report. Clin Cosmet Investig Dermatol 16:1089\u20131094. https:\/\/doi.org\/10.2147\/CCID.S392909","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"3621_CR43","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS, Strategy ORAL, investigators, (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390:457\u2013468. https:\/\/doi.org\/10.1016\/S0140-6736(17)31618-5","journal-title":"Lancet"},{"key":"3621_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/17425255.2022.2099835","volume":"18","author":"L Calabrese","year":"2022","unstructured":"Calabrese L, Chiricozzi A, De Simone C, Fossati B, D\u2019Amore A, Peris K (2022) Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis. Expert Opin Drug Metab Toxicol 18:347\u2013355. https:\/\/doi.org\/10.1080\/17425255.2022.2099835","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3621_CR45","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1002\/art.41906","volume":"73","author":"C Liu","year":"2021","unstructured":"Liu C, Kieltyka J, Fleischmann R, Gadina M, O\u2019Shea JJ (2021) A decade of JAK inhibitors: what have we learned and what may be the future? Arthritis Rheumatol 73:2166\u20132178. https:\/\/doi.org\/10.1002\/art.41906","journal-title":"Arthritis Rheumatol"},{"key":"3621_CR46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368:161\u2013170. https:\/\/doi.org\/10.1056\/NEJMra1202117","journal-title":"N Engl J Med"},{"key":"3621_CR47","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/JLB.5RI0218-084R","volume":"104","author":"M Gadina","year":"2018","unstructured":"Gadina M, Johnson C, Schwartz D, Bonelli M, Hasni S, Kanno Y, Changelian P, Laurence A, O\u2019Shea JJ (2018) Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. J Leukoc Biol 104:499\u2013514. https:\/\/doi.org\/10.1002\/JLB.5RI0218-084R","journal-title":"J Leukoc Biol"},{"key":"3621_CR48","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jbspin.2015.09.002","volume":"83","author":"H Wu","year":"2016","unstructured":"Wu H, Yan S, Chen J, Luo X, Li P, Jia X, Dai X, Wang C, Huang Q, Liu L, Zhang Y, Zhou A, Chang Y, Zhang L, Wei W (2016) JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells. Joint Bone Spine 83:525\u2013532. https:\/\/doi.org\/10.1016\/j.jbspin.2015.09.002","journal-title":"Joint Bone Spine"},{"key":"3621_CR49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cyto.2015.09.017","volume":"77","author":"S Tavakolpour","year":"2016","unstructured":"Tavakolpour S, Tavakolpour V (2016) Interleukin 4 inhibition as a potential therapeutic in pemphigus. Cytokine 77:189\u2013195. https:\/\/doi.org\/10.1016\/j.cyto.2015.09.017","journal-title":"Cytokine"},{"key":"3621_CR50","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaut.2013.06.007","volume":"45","author":"H Dooms","year":"2013","unstructured":"Dooms H (2013) Interleukin-7: Fuel for the autoimmune attack. J Autoimmun 45:40\u201348. https:\/\/doi.org\/10.1016\/j.jaut.2013.06.007","journal-title":"J Autoimmun"},{"key":"3621_CR51","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cytogfr.2013.09.001","volume":"24","author":"HF Pan","year":"2013","unstructured":"Pan HF, Leng RX, Li XP, Zheng SG, Ye DQ (2013) Targeting T-helper 9 cells and interleukin-9 in autoimmune diseases. Cytokine Growth Factor Rev 24:515\u2013522. https:\/\/doi.org\/10.1016\/j.cytogfr.2013.09.001","journal-title":"Cytokine Growth Factor Rev"},{"key":"3621_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.intimp.2016.11.005","volume":"42","author":"S Tavakolpour","year":"2017","unstructured":"Tavakolpour S, Kheiry F, Mirsafaei HS, Akhlaghdoust M (2017) The possible role of interleukin-35 and its therapeutic potential in pemphigus. Int Immunopharmacol 42:11\u201317. https:\/\/doi.org\/10.1016\/j.intimp.2016.11.005","journal-title":"Int Immunopharmacol"},{"key":"3621_CR53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.intimp.2016.02.020","volume":"34","author":"S Tavakolpour","year":"2016","unstructured":"Tavakolpour S (2016) Interleukin 21 as a new possible player in pemphigus: is it a suitable target? Int Immunopharmacol 34:139\u2013145. https:\/\/doi.org\/10.1016\/j.intimp.2016.02.020","journal-title":"Int Immunopharmacol"},{"key":"3621_CR54","doi-asserted-by":"publisher","first-page":"102906","DOI":"10.1016\/j.autrev.2021.102906","volume":"20","author":"H Long","year":"2021","unstructured":"Long H, Liao J, Yang M, Wang X, Zhang G, Lu Q (2021) Low-dose interleukin-2: a potential treatment for pemphigus vulgaris. Autoimmun Rev 20:102906. https:\/\/doi.org\/10.1016\/j.autrev.2021.102906","journal-title":"Autoimmun Rev"},{"key":"3621_CR55","doi-asserted-by":"publisher","first-page":"e14605","DOI":"10.1111\/dth.14605","volume":"34","author":"RM Bakr","year":"2021","unstructured":"Bakr RM, Sayed DS, Abd-Elkader AS, Kamel AA, Badran AY (2021) Does interleukin-33 level correlate with the activity of pemphigus vulgaris?: a case-control study. Dermatol Ther 34:e14605. https:\/\/doi.org\/10.1111\/dth.14605","journal-title":"Dermatol Ther"},{"key":"3621_CR56","doi-asserted-by":"publisher","first-page":"6716419","DOI":"10.1155\/2017\/6716419","volume":"2017","author":"K Juczynska","year":"2017","unstructured":"Juczynska K, Wozniacka A, Waszczykowska E, Danilewicz M, Wagrowska-Danilewicz M, Wieczfinska J, Pawliczak R, Zebrowska A (2017) Expression of the JAK\/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis. Mediators Inflamm 2017:6716419. https:\/\/doi.org\/10.1155\/2017\/6716419","journal-title":"Mediators Inflamm"},{"key":"3621_CR57","doi-asserted-by":"publisher","first-page":"106737","DOI":"10.1016\/j.intimp.2020.106737","volume":"86","author":"Y Li","year":"2020","unstructured":"Li Y, Liu X, Yu J, Li Z, Chen Y, Li H, Chen X, Su W, Liang D (2020) Tofacitinib suppresses mast cell degranulation and attenuates experimental allergic conjunctivitis. Int Immunopharmacol 86:106737. https:\/\/doi.org\/10.1016\/j.intimp.2020.106737","journal-title":"Int Immunopharmacol"},{"key":"3621_CR58","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, Chen S, Trier AM, Xu AZ, Tripathi SV, Luo J, Gao X, Yang L, Hamilton SL, Wang PL, Brestoff JR, Council ML, Brasington R, Schaffer A, Brombacher F, Hsieh CS, Gereau RW, Miller MJ, Chen ZF, Hu H, Davidson S, Liu Q, Kim BS (2017) Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell 171:217-228.e13. https:\/\/doi.org\/10.1016\/j.cell.2017.08.006","journal-title":"Cell"},{"key":"3621_CR59","doi-asserted-by":"publisher","first-page":"738481","DOI":"10.3389\/fimmu.2021.738481","volume":"12","author":"M Palmroth","year":"2021","unstructured":"Palmroth M, Kuuliala K, Peltomaa R, Virtanen A, Kuuliala A, Kurttila A, Kinnunen A, Leirisalo-Repo M, Silvennoinen O, Isom\u00e4ki P (2021) Tofacitinib suppresses several JAK-STAT pathways in rheumatoid arthritis in vivo and baseline signaling profile associates with treatment response. Front Immunol 12:738481. https:\/\/doi.org\/10.3389\/fimmu.2021.738481","journal-title":"Front Immunol"},{"key":"3621_CR60","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1111\/jdv.14002","volume":"31","author":"J Loget","year":"2017","unstructured":"Loget J, Pl\u00e9e J, Antonicelli F, Bernard P (2017) A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis. J Eur Acad Dermatol Venereol 31:e228\u2013e230. https:\/\/doi.org\/10.1111\/jdv.14002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3621_CR61","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","volume":"10","author":"MD Howell","year":"2019","unstructured":"Howell MD, Kuo FI, Smith PA (2019) Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol 10:2342. https:\/\/doi.org\/10.3389\/fimmu.2019.02342","journal-title":"Front Immunol"},{"key":"3621_CR62","doi-asserted-by":"publisher","first-page":"8112","DOI":"10.1167\/iovs.11-9322","volume":"53","author":"AM Suelves","year":"2012","unstructured":"Suelves AM, Zhao TZ, Siddique SS, Foster CS (2012) Profile of local interleukin expression in a cohort of ocular cicatricial pemphigoid patients. Invest Ophthalmol Vis Sci 53:8112\u20138117. https:\/\/doi.org\/10.1167\/iovs.11-9322","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3621_CR63","doi-asserted-by":"publisher","first-page":"8468","DOI":"10.1021\/jm1004286","volume":"53","author":"ME Flanagan","year":"2010","unstructured":"Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa C, Doty JL, Elliott EA, Fisher MB, Hines M, Kent C, Kudlacz EM, Lillie BM, Magnuson KS, McCurdy SP, Munchhof MJ, Perry BD, Sawyer PS, Strelevitz TJ, Subramanyam C, Sun J, Whipple DA, Changelian PS (2010) Discovery of CP-690,550: A potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 53:8468\u20138484. https:\/\/doi.org\/10.1021\/jm1004286","journal-title":"J Med Chem"},{"key":"3621_CR64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","volume":"15","author":"F Seif","year":"2017","unstructured":"Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M (2017) The role of JAK-STAT signaling pathway and its regulators in the fate of T Helper Cells. Cell Commun Signal 15:23. https:\/\/doi.org\/10.1186\/s12964-017-0177-y","journal-title":"Cell Commun Signal"},{"key":"3621_CR65","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.ajoc.2021.101104","volume":"22","author":"H James","year":"2021","unstructured":"James H, Paley GL, Brasington R, Custer PL, Margolis TP, Paley MA (2021) Tofacitinib for refractory ocular mucous membrane pemphigoid. Am J Ophthalmol Case Rep 22:101104. https:\/\/doi.org\/10.1016\/j.ajoc.2021.101104","journal-title":"Am J Ophthalmol Case Rep"},{"key":"3621_CR66","doi-asserted-by":"publisher","first-page":"642","DOI":"10.2340\/00015555-2604","volume":"97","author":"T Makino","year":"2017","unstructured":"Makino T, Yoshihisa Y, Mizawa M, Tsutsui K, Nishijima C, Inaoki M, Shimizu T (2017) Increased serum levels of Th2-type cytokines and eotaxin in fibrillar-type dermatitis herpetiformis. Acta Derm Venereol 97:642\u2013643. https:\/\/doi.org\/10.2340\/00015555-2604","journal-title":"Acta Derm Venereol"},{"key":"3621_CR67","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1365-2133.1993.tb00479.x","volume":"129","author":"M Graeber","year":"1993","unstructured":"Graeber M, Baker BS, Garioch JJ, Valdimarsson H, Leonard JN, Fry L (1993) The role of cytokines in the generation of skin lesions in dermatitis herpetiformis. Br J Dermatol 129:530\u2013532. https:\/\/doi.org\/10.1111\/j.1365-2133.1993.tb00479.x","journal-title":"Br J Dermatol"},{"key":"3621_CR68","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1046\/j.1365-2133.1998.02068.x","volume":"138","author":"M Caproni","year":"1998","unstructured":"Caproni M, Feliciani C, Fuligni A, Salvatore E, Atani L, Bianchi B, Pour SM, Proietto G, Toto P, Coscione G, Amerio P, Fabbri P (1998) Th2-like cytokine activity in dermatitis herpetiformis. Br J Dermatol 138:242\u2013247. https:\/\/doi.org\/10.1046\/j.1365-2133.1998.02068.x","journal-title":"Br J Dermatol"},{"key":"3621_CR69","doi-asserted-by":"publisher","first-page":"5965492","DOI":"10.1155\/2017\/5965492","volume":"2017","author":"L Kulczycka-Siennicka","year":"2017","unstructured":"Kulczycka-Siennicka L, Cynkier A, Waszczykowska E, Wo\u017aniacka A, \u017bebrowska A (2017) The role of Intereukin-31 in pathogenesis of itch and its intensity in a course of bullous pemphigoid and dermatitis herpetiformis. BioMed Res Int 2017:5965492. https:\/\/doi.org\/10.1155\/2017\/5965492","journal-title":"BioMed Res Int"},{"key":"3621_CR70","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/1523-1747.ep12481904","volume":"97","author":"MM Ward","year":"1991","unstructured":"Ward MM, Pisetsky DS, Hall RP (1991) Soluble interleukin-2 receptor levels in patients with dermatitis herpetiformis. J Invest Dermatol 97:568\u2013572. https:\/\/doi.org\/10.1111\/1523-1747.ep12481904","journal-title":"J Invest Dermatol"},{"key":"3621_CR71","doi-asserted-by":"publisher","first-page":"331","DOI":"10.5114\/ceji.2014.45944","volume":"39","author":"J Gornowicz-Porowska","year":"2014","unstructured":"Gornowicz-Porowska J, Bowszyc-Dmochowska M, Seraszek-Jaros A, Kaczmarek E, Pietkiewicz P, Dmochowski M (2014) Cutaneous expressions of interleukin-6 and neutrophil elastase as well as levels of serum IgA antibodies to gliadin nonapeptides, tissue transglutaminase and epidermal transglutaminase: Implications for both autoimmunity and autoinflammation involvement in dermatitis herpetiformis. Cent Eur J Immunol 39:331\u2013337. https:\/\/doi.org\/10.5114\/ceji.2014.45944","journal-title":"Cent Eur J Immunol"},{"key":"3621_CR72","doi-asserted-by":"publisher","first-page":"967987","DOI":"10.1155\/2013\/967987","volume":"2013","author":"A Zebrowska","year":"2013","unstructured":"Zebrowska A, Wagrowska-Danilewicz M, Danilewicz M, Stasikowska-Kanicka O, Cynkier A, Sysa-Jedrzejowska A, Waszczykowska E (2013) IL-17 expression in dermatitis herpetiformis and bullous pemphigoid. Mediators Inflamm 2013:967987. https:\/\/doi.org\/10.1155\/2013\/967987","journal-title":"Mediators Inflamm"},{"key":"3621_CR73","doi-asserted-by":"publisher","unstructured":"Kahn JS, Moody K, Rosmarin D (2021) Significant improvement of dermatitis herpetiformis with tofacitinib. Dermatol Online J 27. https:\/\/doi.org\/10.5070\/D327754365","DOI":"10.5070\/D327754365"},{"key":"3621_CR74","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1001\/jamadermatol.2021.0762","volume":"157","author":"M Becker","year":"2021","unstructured":"Becker M, Schumacher N, Schmidt E, Zillikens D, Sadik CD (2021) Evaluation and comparison of clinical and iLaboratory characteristics of patients with IgA epidermolysis bullosa acquisita, linear IgA bullous dermatosis, and IgG epidermolysis bullosa acquisita. JAMA Dermatol 157:917\u2013923. https:\/\/doi.org\/10.1001\/jamadermatol.2021.0762","journal-title":"JAMA Dermatol"},{"issue":"Supplement 1","key":"3621_CR75","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1590\/abd1806-4841.2019940208","volume":"94","author":"ECSD Vale","year":"2019","unstructured":"Vale ECSD, Dimatos OC, Porro AM, Santi CG (2019) Consensus on the treatment of autoimmune bullous dermatoses: dermatitis herpetiformis and linear IgA bullous dermatosis - Brazilian society of dermatology. An Bras Dermatol 94(Supplement 1):48\u201355. https:\/\/doi.org\/10.1590\/abd1806-4841.2019940208","journal-title":"An Bras Dermatol"},{"key":"3621_CR76","doi-asserted-by":"publisher","first-page":"e6998","DOI":"10.1002\/ccr3.6998","volume":"11","author":"SC Jordan","year":"2023","unstructured":"Jordan SC, Balzer B, Nast C, Atienza J, Lim K, Kumar S, Nissen N, Shin B (2023) Linear IgA bullous dermatosis and elevated bullous interleukin-6 levels: responsive to treatment with anti-IL-6 receptor monoclonals. Clin Case Rep 11:e6998. https:\/\/doi.org\/10.1002\/ccr3.6998","journal-title":"Clin Case Rep"},{"key":"3621_CR77","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/s0190-9622(96)90106-1","volume":"35","author":"A Tranvan","year":"1996","unstructured":"Tranvan A, Pezen DS, Medenica M, Michelson GC, Vogelzang N, Soltani KM (1996) Interleukin-2 associated linear IgA bullous dermatosis. J Am Acad Dermatol 35:865\u2013867. https:\/\/doi.org\/10.1016\/s0190-9622(96)90106-1","journal-title":"J Am Acad Dermatol"},{"key":"3621_CR78","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.1987.03400120074028","volume":"258","author":"AA Gaspari","year":"1987","unstructured":"Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI (1987) Dermatologic changes associated with interleukin 2 administration. JAMA 258:1624\u20131629. https:\/\/doi.org\/10.1001\/jama.1987.03400120074028","journal-title":"JAMA"},{"key":"3621_CR79","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/bjd.12517","volume":"169","author":"B Strober","year":"2013","unstructured":"Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R, Valdez H, Langley RG, Harness J, Menter A, Papp K (2013) Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 169:992\u2013999. https:\/\/doi.org\/10.1111\/bjd.12517","journal-title":"Br J Dermatol"},{"key":"3621_CR80","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/path.2157","volume":"212","author":"MT Chiriac","year":"2007","unstructured":"Chiriac MT, Roesler J, Sindrilaru A, Scharffetter-Kochanek K, Zillikens D, Sitaru C (2007) NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage. J Pathol 212:56\u201365. https:\/\/doi.org\/10.1002\/path.2157","journal-title":"J Pathol"},{"key":"3621_CR81","doi-asserted-by":"publisher","first-page":"559","DOI":"10.4049\/jimmunol.1301556","volume":"192","author":"UK Samavedam","year":"2014","unstructured":"Samavedam UK, Iwata H, M\u00fcller S, Schulze FS, Recke A, Schmidt E, Zillikens D, Ludwig RJ (2014) GM-CSF modulates autoantibody production and skin blistering in experimental epidermolysis bullosa acquisita. J Immunol 192:559\u2013571. https:\/\/doi.org\/10.4049\/jimmunol.1301556","journal-title":"J Immunol"},{"key":"3621_CR82","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/13543784.2019.1551358","volume":"28","author":"CC Mok","year":"2019","unstructured":"Mok CC (2019) The jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs 28:85\u201392. https:\/\/doi.org\/10.1080\/13543784.2019.1551358","journal-title":"Expert Opin Investig Drugs"},{"key":"3621_CR83","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/art.39818","volume":"69","author":"Y Furumoto","year":"2017","unstructured":"Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG, Abdalrahman Z, Scium\u00e8 G, Tsai WL, Trier AM, Nunez L, Mast L, Hoffmann V, Remaley AT, O\u2019Shea JJ, Kaplan MJ, Gadina M (2017) Tofacitinib ameliorates murine lupus and its associated vascular dysfunction. Arthritis Rheumatol 69:148\u2013160. https:\/\/doi.org\/10.1002\/art.39818","journal-title":"Arthritis Rheumatol"},{"key":"3621_CR84","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","volume":"12","author":"SA Hasni","year":"2021","unstructured":"Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, Wang X, Naqi M, Playford MP, Goel RR, Li X, Biehl AJ, Ochoa-Navas I, Manna Z, Shi Y, Thomas D, Chen J, Biancotto A, Apps R, Cheung F, Kotliarov Y, Babyak AL, Zhou H, Shi R, Stagliano K, Tsai WL, Vian L, Gazaniga N, Giudice V, Lu S, Brooks SR, MacKay M, Gregersen P, Mehta NN, Remaley AT, Diamond B, O\u2019Shea JJ, Gadina M, Kaplan MJ (2021) Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun 12:3391. https:\/\/doi.org\/10.1038\/s41467-021-23361-z","journal-title":"Nat Commun"},{"key":"3621_CR85","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/annrheumdis-2019-215455","volume":"78","author":"H You","year":"2019","unstructured":"You H, Zhang G, Wang Q, Zhang S, Zhao J, Tian X, Li H, Li M, Zeng X (2019) Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis 78:1441\u20131443. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215455","journal-title":"Ann Rheum Dis"},{"key":"3621_CR86","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.cyto.2018.10.023","volume":"113","author":"R Pescarmona","year":"2019","unstructured":"Pescarmona R, Belot A, Villard M, Besson L, Lopez J, Mosnier I, Mathieu AL, Lombard C, Garnier L, Frachette C, Walzer T, Viel S (2019) Comparison of RT-qPCR and nanostring in the measurement of blood interferon response for the diagnosis of Type I interferonopathies. Cytokine 113:446\u2013452. https:\/\/doi.org\/10.1016\/j.cyto.2018.10.023","journal-title":"Cytokine"},{"key":"3621_CR87","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/ard.2011.150284","volume":"71","author":"S Rosengren","year":"2012","unstructured":"Rosengren S, Corr M, Firestein GS, Boyle DL (2012) The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of Type I interferon. Ann Rheum Dis 71:440\u2013447. https:\/\/doi.org\/10.1136\/ard.2011.150284","journal-title":"Ann Rheum Dis"},{"key":"3621_CR88","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/art.41944","volume":"74","author":"JJ Paik","year":"2022","unstructured":"Paik JJ, Shneyderman M, Gutierrez-Alamillo L, Albayda J, Tiniakou E, Perin J, Purwin G, Leung S, Leung D, Casciola-Rosen L, Koenig AS, Christopher-Stine L (2022) Long-term extension study of tofacitinib in refractory dermatomyositis. Arthritis Rheumatol 74:371\u2013372. https:\/\/doi.org\/10.1002\/art.41944","journal-title":"Arthritis Rheumatol"},{"key":"3621_CR89","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jaad.2021.07.003","volume":"86","author":"MS Min","year":"2022","unstructured":"Min MS, Alsarheed A, Kassamali B, Mazori DR, Schaefer M, Merola JF, Cobos G, LaChance AH, Vleugels RA (2022) Tofacitinib as treatment for refractory dermatomyositis: a retrospective study from 2 academic medical centers. J Am Acad Dermatol 86:423\u2013425. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.003","journal-title":"J Am Acad Dermatol"},{"key":"3621_CR90","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40257-020-00502-6","volume":"21","author":"GA Cobos","year":"2020","unstructured":"Cobos GA, Femia A, Vleugels RA (2020) Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol 21:339\u2013353. https:\/\/doi.org\/10.1007\/s40257-020-00502-6","journal-title":"Am J Clin Dermatol"},{"key":"3621_CR91","doi-asserted-by":"publisher","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","volume":"12","author":"A Nombel","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F (2021) Dermatomyositis with anti-MDA5 antibodies: Bioclinical features, pathogenesis and emerging therapies. Front Immunol 12:773352. https:\/\/doi.org\/10.3389\/fimmu.2021.773352","journal-title":"Front Immunol"},{"key":"3621_CR92","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s10067-023-06567-y","volume":"42","author":"Y Wang","year":"2023","unstructured":"Wang Y, Luo J, Lv X, Li Y, An Q, Mo L, Hu N, Zhang J, Wang J, Tian J, Pu D, Hao Z, He L (2023) Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis. Clin Rheumatol 42:1847\u20131853. https:\/\/doi.org\/10.1007\/s10067-023-06567-y","journal-title":"Clin Rheumatol"},{"key":"3621_CR93","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.4065\/70.11.1068","volume":"70","author":"LS Peterson","year":"1995","unstructured":"Peterson LS, Nelson AM, Su WP (1995) Classification of morphea (localized Scleroderma). Mayo Clin Proc 70:1068\u20131076. https:\/\/doi.org\/10.4065\/70.11.1068","journal-title":"Mayo Clin Proc"},{"key":"3621_CR94","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1074\/jbc.M116.773085","volume":"292","author":"LY Tang","year":"2017","unstructured":"Tang LY, Heller M, Meng Z, Yu LR, Tang Y, Zhou M, Zhang YE (2017) Transforming growth factor-\u03b2 (TGF-\u03b2) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway. J Biol Chem 292:4302\u20134312. https:\/\/doi.org\/10.1074\/jbc.M116.773085","journal-title":"J Biol Chem"},{"key":"3621_CR95","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","volume":"8","author":"D Chakraborty","year":"2017","unstructured":"Chakraborty D, \u0160umov\u00e1 B, Mallano T, Chen CW, Distler A, Bergmann C, Ludolph I, Horch RE, Gelse K, Ramming A, Distler O, Schett G, \u0160enolt L, Distler JHW (2017) Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun 8:1130. https:\/\/doi.org\/10.1038\/s41467-017-01236-6","journal-title":"Nat Commun"},{"key":"3621_CR96","first-page":"567","volume":"38","author":"XY Cao","year":"2020","unstructured":"Cao XY, Zhao JL, Hou Y, Wang FD, Lu ZH (2020) Janus kinase inhibitor tofacitinib is a potential therapeutic option for refractory eosinophilic fasciitis. Clin Exp Rheumatol 38:567\u2013568","journal-title":"Clin Exp Rheumatol"},{"key":"3621_CR97","first-page":"75","volume":"28","author":"JF Viallard","year":"2001","unstructured":"Viallard JF, Taupin JL, Ranchin V, Leng B, Pellegrin JL, Moreau JF (2001) Analysis of leukemia inhibitory factor, Type 1 and Type 2 cytokine production in patients with eosinophilic fasciitis. J Rheumatol 28:75\u201380","journal-title":"J Rheumatol"},{"key":"3621_CR98","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/s0190-9622(03)00447-x","volume":"49","author":"LE French","year":"2003","unstructured":"French LE, Shapiro M, Junkins-Hopkins JM, Wolfe JT, Rook AH (2003) Eosinophilic fasciitis and eosinophilic cellulitis in a patient with abnormal circulating clonal T cells: increased production of interleukin 5 and inhibition by interferon alfa. J Am Acad Dermatol 49:1170\u20131174. https:\/\/doi.org\/10.1016\/s0190-9622(03)00447-x","journal-title":"J Am Acad Dermatol"},{"key":"3621_CR99","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A (2015) The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66:311\u2013328. https:\/\/doi.org\/10.1146\/annurev-med-051113-024537","journal-title":"Annu Rev Med"},{"key":"3621_CR100","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","volume":"79","author":"Q Hu","year":"2020","unstructured":"Hu Q, Wang M, Jia J, Teng J, Chi H, Liu T, Liu HL, Cheng X, Ye J, Su Y, Sun Y, Zhou Z, Wan L, Wang Z, Wang F, Shi H, Yang C (2020) Tofacitinib in refractory adult-onset Still\u2019s disease: 14 cases from a single centre in China. Ann Rheum Dis 79:842\u2013844. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216699","journal-title":"Ann Rheum Dis"},{"key":"3621_CR101","doi-asserted-by":"publisher","unstructured":"Po-Ku Chen, Shiow-Jiuan Wey, Der-Yuan Chen (2022) Interleukin-18: a biomarker with therapeutic potential in adult-onset Still\u2019s disease.Expert review of clinical immunology 18:823\u2013833. https:\/\/doi.org\/10.1080\/1744666X.2022.2096592","DOI":"10.1080\/1744666X.2022.2096592"},{"key":"3621_CR102","doi-asserted-by":"publisher","first-page":"R102","DOI":"10.1186\/ar4551","volume":"16","author":"H Marotte","year":"2014","unstructured":"Marotte H, Tsou PS, Fedorova T, Pinney AJ, Lewis B, Koch AE (2014) Blocking the Janus-activated kinase pathway reduces tumor necrosis factor alpha-induced interleukin-18 bioactivity by caspase-1 inhibition. Arthritis Res Ther 16:R102. https:\/\/doi.org\/10.1186\/ar4551","journal-title":"Arthritis Res Ther"},{"key":"3621_CR103","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1164\/rccm.201903-0659OC","volume":"201","author":"E Verweyen","year":"2020","unstructured":"Verweyen E, Holzinger D, Weinhage T, Hinze C, Wittkowski H, Pickkers P, Albeituni S, Verbist K, Nichols KE, Schulert G, Grom A (2020) Synergistic signaling of TLR and IFN\u03b1\/\u03b2 facilitates escape of IL-18 expression from endotoxin tolerance. Am J Respir Crit Care Med 201:526\u2013539. https:\/\/doi.org\/10.1164\/rccm.201903-0659OC","journal-title":"Am J Respir Crit Care Med"},{"key":"3621_CR104","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/rheumatology\/keaa670","volume":"60","author":"MJ Barrera","year":"2021","unstructured":"Barrera MJ, Aguilera S, Castro I, Matus S, Carvajal P, Molina C, Gonz\u00e1lez S, Jara D, Hermoso M, Gonz\u00e1lez MJ (2021) Tofacitinib counteracts IL-6 overexpression induced by deficient autophagy: implications in Sj\u00f6gren\u2019s syndrome. Rheumatol (Oxf Engl) 60:1951\u20131962. https:\/\/doi.org\/10.1093\/rheumatology\/keaa670","journal-title":"Rheumatol (Oxf Engl)"},{"key":"3621_CR105","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s11739-021-02688-x","volume":"16","author":"P Fraticelli","year":"2021","unstructured":"Fraticelli P, Benfaremo D, Gabrielli A (2021) Diagnosis and management of leukocytoclastic vasculitis. Intern Emerg Med 16:831\u2013841. https:\/\/doi.org\/10.1007\/s11739-021-02688-x","journal-title":"Intern Emerg Med"},{"key":"3621_CR106","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","volume":"59","author":"H You","year":"2020","unstructured":"You H, Xu D, Zhao J, Li J, Wang Q, Tian X, Li M, Zeng X (2020) JAK inhibitors: prospects in connective tissue diseases. Clin Rev Allergy Immunol 59:334\u2013351. https:\/\/doi.org\/10.1007\/s12016-020-08786-6","journal-title":"Clin Rev Allergy Immunol"},{"key":"3621_CR107","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1007\/s10067-021-05707-6","volume":"40","author":"Y Ding","year":"2021","unstructured":"Ding Y, Zhou Y, Li HR, Xiong YH, Yin W, Zhao L (2021) Characteristics of immune function in the acute phase of Henoch-Sch\u00f6nlein purpura. Clin Rheumatol 40:3711\u20133716. https:\/\/doi.org\/10.1007\/s10067-021-05707-6","journal-title":"Clin Rheumatol"},{"key":"3621_CR108","first-page":"12","volume":"37","author":"D Xu","year":"2019","unstructured":"Xu D, Liu X, Lu C, Luo J, Wang C, Gao C, Xie J, Li X (2019) Reduction of peripheral natural killer cells in patients with SAPHO syndrome. Clin Exp Rheumatol 37:12\u201318","journal-title":"Clin Exp Rheumatol"},{"key":"3621_CR109","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1399-3038.2011.01198.x","volume":"22","author":"HY Jen","year":"2011","unstructured":"Jen HY, Chuang YH, Lin SC, Chiang BL, Yang YH (2011) Increased serum interleukin-17 and peripheral Th17 Cells in children with acute Henoch-Sch\u00f6nlein purpura. Pediatr Allergy Immunol 22:862\u2013868. https:\/\/doi.org\/10.1111\/j.1399-3038.2011.01198.x","journal-title":"Pediatr Allergy Immunol"},{"key":"3621_CR110","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3109\/08916934.2014.906582","volume":"47","author":"D Firinu","year":"2014","unstructured":"Firinu D, Barca MP, Lorrai MM, Perra S, Cabras S, Muggianu E, Di Martino ML, Manconi PE, Del Giacco SR (2014) TH17 cells are increased in the peripheral blood of patients with SAPHO syndrome. Autoimmunity 47:389\u2013394. https:\/\/doi.org\/10.3109\/08916934.2014.906582","journal-title":"Autoimmunity"},{"key":"3621_CR111","doi-asserted-by":"publisher","first-page":"937","DOI":"10.5114\/ada.2020.97394","volume":"38","author":"H Przepiera-B\u0119dzak","year":"2021","unstructured":"Przepiera-B\u0119dzak H, Brzosko M (2021) SAPHO syndrome: Pathogenesis, clinical presentation, imaging, comorbidities and treatment: a review. Postepy Dermatol Alergol 38:937\u2013942. https:\/\/doi.org\/10.5114\/ada.2020.97394","journal-title":"Postepy Dermatol Alergol"},{"key":"3621_CR112","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/ced.12089","volume":"38","author":"S Kimura","year":"2013","unstructured":"Kimura S, Takeuchi S, Soma Y, Kawakami T (2013) Raised serum levels of interleukins 6 and 8 and antiphospholipid antibodies in an adult patient with HenochSch\u00f6nlein purpura. Clin Exp Dermatol 38:730\u2013736. https:\/\/doi.org\/10.1111\/ced.12089","journal-title":"Clin Exp Dermatol"},{"issue":"Supplement 57","key":"3621_CR113","first-page":"114","volume":"28","author":"O Torres","year":"2010","unstructured":"Torres O, Palomino-Morales R, Miranda-Filloy JA, Vazquez-Rodriguez TR, Martin J, Gonzalez-Gay MA (2010) IL-18 gene polymorphisms in Henoch-Sch\u00f6nlein purpura. Clin Exp Rheumatol 28(Supplement 57):114","journal-title":"Clin Exp Rheumatol"},{"key":"3621_CR114","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/art.39037","volume":"67","author":"D Saadoun","year":"2015","unstructured":"Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, Terrier B, Geri G, Rosenzwajg M, Klatzmann D, Fourret P, Cluzel P, Chiche L, Gaudric J, Koskas F, Cacoub P (2015) Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol 67:1353\u20131360. https:\/\/doi.org\/10.1002\/art.39037","journal-title":"Arthritis Rheumatol"},{"key":"3621_CR115","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O\u2019Shea JJ (2011) Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186:4234\u20134243. https:\/\/doi.org\/10.4049\/jimmunol.1003668","journal-title":"J Immunol"},{"key":"3621_CR116","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/BOR.0000000000000004","volume":"26","author":"A Clifford","year":"2014","unstructured":"Clifford A, Hoffman GS (2014) Recent advances in the medical management of Takayasu arteritis: an update on the use of biologic therapies. Curr Opin Rheumatol 26:7\u201315. https:\/\/doi.org\/10.1097\/BOR.0000000000000004","journal-title":"Curr Opin Rheumatol"},{"key":"3621_CR117","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.autrev.2011.11.026","volume":"11","author":"M Pineton de Chambrun","year":"2012","unstructured":"Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D (2012) New insights into the pathogenesis of Beh\u00e7et\u2019s disease. Autoimmun Rev 11:687\u2013698. https:\/\/doi.org\/10.1016\/j.autrev.2011.11.026","journal-title":"Autoimmun Rev"},{"key":"3621_CR118","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/gene.2014.64","volume":"16","author":"A Tulunay","year":"2015","unstructured":"Tulunay A, Dozmorov MG, Ture-Ozdemir F, Yilmaz V, Eksioglu-Demiralp E, Alibaz-Oner F, Ozen G, Wren JD, Saruhan-Direskeneli G, Sawalha AH, Direskeneli H (2015) Activation of the JAK\/STAT pathway in Behcet\u2019s disease. Genes Immun 16:170\u2013175. https:\/\/doi.org\/10.1038\/gene.2014.64","journal-title":"Genes Immun"},{"key":"3621_CR119","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1136\/annrheumdis-2016-209330","volume":"75","author":"D Rimar","year":"2016","unstructured":"Rimar D, Alpert A, Starosvetsky E, Rosner I, Slobodin G, Rozenbaum M, Kaly L, Boulman N, Awisat A, Ginsberg S, Zilber K, Shen-Orr SS (2016) Tofacitinib for polyarteritis nodosa: a tailored therapy. Ann Rheum Dis 75:2214\u20132216. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209330","journal-title":"Ann Rheum Dis"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03621-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03621-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03621-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T08:33:59Z","timestamp":1710318839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03621-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["3621"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03621-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2024,1,17]]},"assertion":[{"value":"18 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this paper.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}